Gimoti™ Prescription Drug User Fee Act (PDUFA) decision date set for June 19, 2020 SOLANA BEACH, Calif. , March 12, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial (Friday) (Friday) … Vomiting and gastric emptying delays can cause unpredictable absorption of food and oral medications, which complicate glucose control and can lead to dehydration and malnutrition. This calendar tracks upcoming PDUFA drug approval dates and FDA advisory committee meetings. In addition, the Company requested a meeting with the FDA prior to the Prescription Drug User Fee Act (PDUFA) action … SOLANA BEACH, Calif. , Sept. 09, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer R .Ph., President and Chief Executive Officer, and Matt D’Onofrio, Chief SOLANA BEACH Calif., March 04, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), today announced the receipt of a multi-disciplinary review (DR) letter from the … Preparing for commercial launch of GIMOTI™ in 4Q 2020 SOLANA BEACH, Calif. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the second quarter Gimoti FDA Approval History. (See Chapter 2.) Gimoti commercial launch on track for the fourth quarter of 2020 SOLANA BEACH, Calif. and CHICAGO , Aug. 25, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases and EVERSANA™, a leading provider of COVID-19 Clinical Trial Tracker . Find and follow all COVID-19 clinical trials. Copyright 2017 Evoke Pharma | All Rights Reserved | Site Developed By SOLANA BEACH, Calif., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (), a specialty pharmaceutical company focused … PDUFA Target Goal Date is June 19, 2020. Has Its Deadliest Day in More Than Two Weeks: Virus UpdateThe coronavirus has sparked a boom in digital health, but some say it may not lastFashion designer Rebecca Minkoff on 2020 NYFW going virtualThe Burger King of the future will revolve around drive-thrus and pick-up windowsPlant Thieves Scour Forests to Satisfy Foliage-Starved Filipinos “We will now turn our focus to ensuring commercial readiness, as we believe physicians and patients are in urgent need of a new treatment option for the management of diabetic gastroparesis. Read More. Gimoti™ Prescription Drug User Fee Act (PDUFA) date is June 19, 2020 SOLANA BEACH, Calif. , May 12, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the SOLANA BEACH, Calif., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (A six-month period of review from the FDA’s date of receipt has been assigned for the resubmitted NDA and the application has been assigned a new Prescription Drug User Fee Act (PDUFA) target goal date of June 19, 2020.“We are pleased that FDA has accepted our NDA resubmission and look forward to working with the Agency throughout the review process toward a potential approval,” commented Dave Gonyer, President and CEO. Other drugs bind to receptors and activate them but do not evoke as great a response as so-called full agonists. These clinical manifestations of gastroparesis have the potential to render existing oral drug treatment options ineffective. Commercial Partner EVERSANA Prepares for GIMOTI Launch Evoke Extends Cash Runway into 2021 SOLANA BEACH, Calif. , June 19, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Evoke Pharma Inc (NASDAQ: EVOK) has a PDUFA date for its Gimoti to treat women with acute and recurrent diabetic gastroparesis. Analytics for Pharma and Biotech Traders. BUSINESS DEVELOPMENT Evoke intends to continue to expand its pipeline of product candidates in its key focus area of gastroenterology disorders. Thus, pindolol, a adrenoceptor "partial agonist," may act as either an agonist (if no full agonist is present) or as an antagonist (if a full agonist such as epinephrine is present). Gimoti™ Prescription Drug User Fee Act (PDUFA) date is June 19, 2020 SOLANA BEACH, Calif. , May 12, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the